This document focuses on contemporary measures, including automated contrast injection (ACI) systems, to prevent contrast-induced nephropathy (CIN) following catheterization and percutaneous coronary intervention (PCI). The use of automated contrast injection systems, such as the ACIST CVi® Contrast Delivery System, can effectively decrease the volume of contrast used during procedures. It remains uncertain whether lower contrast volume is associated with a reduced incidence of CIN; however, a trial was conducted at Wake Forest University Medical Center involving 1,798 patients who underwent diagnostic catheterization or PCI using handheld manifold injection systems, followed by 377 subsequent patients utilizing an automated contrast injection system. The study’s findings demonstrate that when combined with contemporary hydration and pharmacologic strategies, the use of an automated contrast injection system significantly reduces both contrast volume and the incidence of CIN. For further details on ACIs, such as CVi®, and their positive impact on mitigating contrast-induced nephropathy, continue reading.
Study Objectives: To evaluate the incidence of contrast-induced nephropathy (CIN) with the use of an automated contrast injection system in conjunction with contemporary measures to prevent CIN after cardiac catheterization and percutaneous coronary intervention (PCI).
Background: The use of automated contrast injection systems can reduce the volume of procedural contrast, but whether lower contrast volume is associated with lower incidence of CIN is uncertain